

FSMA

FINANCIAL SERVICES AND
MARKETS AUTHORITYTransparency notification
Form TR-1 BE
PART I

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

07/06/2024 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

15

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10


9) Denominator

12,275,690,851

 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	2,377,763,043	1,785,024,954	0	14.54%	0.00%
TOTAL		1,785,024,954	0	14.54%	0.00%

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction						
	Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
TOTAL					0	0.00%	

 **The totals** will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	1,785,024,954	14.54%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)


13) Additional information

On 22 May 2024 (with settlement date on 24 May 2024), Atlas Special Opportunities LLC sold 203,850,000 in Oxurion NV, as a result of which its shareholding decreased to 2,173,913,043 shares (= 17.71%, denominator = 12,275,690,851).
 On 24 May 2024 (with settlement date on 28 May 2024), Atlas Special Opportunities LLC sold 105,913,043 shares in Oxurion NV, as a result of which its shareholding decreased to 2,068,000,000 shares (= 16.85%, denominator = 12,275,690,851).
 On 31 May 2024 (with settlement date on 4 June 2024), Atlas Special Opportunities LLC sold 89,000,000 shares in Oxurion NV, as a result of which its shareholding decreased to 1,979,000,000 shares (= 16.12%, denominator = 12,275,690,851).
 On 3 June 2024 (with settlement date on 5 June 2024), Atlas Special Opportunities LLC sold 68,899,160 shares in Oxurion NV, as a result of which its shareholding decreased to 1,910,100,840 shares (=15.56%, denominator = 12,275,690,851).
 On 5 June 2024 (with settlement date on 7 June 2024), Atlas Special Opportunities LLC sold 125,075,886 shares in Oxurion NV, as a result of which its shareholding decreased to 1,785,024,954 shares (=14.54%, denominator = 12,275,690,851).

Done at

On (DD/MM/YYYY)

Name & capacity

DocuSigned by:
 Signature 
AEF8ADE154024BB...

For security reasons, the unsigned form in **xlsx** format should be transmitted to trp.fin@fsma.be. You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in **PDF** format should also be transmitted.